Applied Molecular Genetics Amgen Inc Shares Crashes

Amgen Inc. shares moved 1.14% to $239.52 Wednesday. This proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.18% to 4,219.55 and Dow Jones Industrial Average DJIA falling 0.44% to 34,447.14.

Amgen Inc. closed $37.17 short of its 52-week high ($276.69), which the company achieved on January 28th. The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson JNJ rose 1.35% to $165.59, Roche Holding AG Part. Cert. RHHVF rose 2.69% to $378.82, and Pfizer Inc. PFE rose 2.47% to $39.81.

Amgen Inc trading volume (3.0 M) eclipsed its 50-day average volume of 2.6 M.Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen on Sunday, setting a price target of 277, which is approximately 16.95% above the present share price of $236.85.Olson expects Amgen to post earnings per share (EPS) of $2.85 for the second quarter of 2021.The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in Amgen, with an average price target of $245.85.The analysts’ price targets range from a high of $301 to a low of $185. The company reported a quarterly revenue of $5.9 billion and a net profit of $2.13 billion. The company’s market cap is $136.08 billion.

Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.